申请人:Sankyo Company, Limited
公开号:US06288059B1
公开(公告)日:2001-09-11
A compound of formula (I), a pharmaceutically acceptable salt or ester or other derivative thereof:
R1 is optionally substituted cycloalkyl or optionally substituted saturated heterocyclic group. R2 is optionally substituted aryl or optionally substituted heteroaryl. A is methylene, carbonyl or sulfonyl. B is a single bond, alkylene or alkenylene. D is oxygen or sulfur. G is alkylene or alkenylene. L is —N(R3)— or —C(R4)(R5)—. R3 is optionally substituted aryl or optionally substituted heteroaryl. R4 is H, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl or optionally substituted saturated heterocyclic group. R5 is alkyl optionally substituted with amino, amino, optionally substituted acylamino, OH, optionally substituted hydroxyalkyl, alkoxy or —CO—R6. R6 is alkyl, alkoxy or amine residue. R4 together with R5 forms a cycloalkane ring, cycloalkene ring, or saturated heterocyclic ring. R7 is alkyl. Z is two hydrogens or oxygen. n is 0. 1 or 2. These compounds have selective antagonistic activity against the NK2 receptor.
一种具有式(I)的化合物,其为药学上可接受的盐或酯或其他衍生物:R1为可选择取代的环烷基或可选择取代的饱和杂环基。R2为可选择取代的芳基或可选择取代的杂芳基。A为亚甲基、羰基或磺酰基。B为单键、烷基或烯基。D为氧或硫。G为烷基或烯基。L为—N(R3)—或—C(R4)(R5)—。R3为可选择取代的芳基或可选择取代的杂芳基。R4为H、可选择取代的芳基、可选择取代的杂芳基、可选择取代的环烷基或可选择取代的饱和杂环基。R5为烷基,可选择取代的氨基、氨基、可选择取代的酰氨基、羟基、可选择取代的羟基烷基、烷氧基或—CO—R6。R6为烷基、烷氧基或胺基残基。R4与R5一起形成环烷烃环、环烯烃环或饱和杂环环。R7为烷基。Z为两个氢原子或氧。n为0、1或2。这些化合物对NK2受体具有选择性拮抗活性。